Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies

F. Marmorino, D. Rossini, S. Lonardi, R. Moretto, G. Zucchelli, G. Aprile, E. Dell'Aquila, M. Ratti, F. Bergamo, G. Masi, F. Urbano, M. Ronzoni, M. Libertini, B. Borelli, G. Randon, A. Buonadonna, G. Allegrini, N. Pella, V. Ricci, A. BoccaccinoT. P. Latiano, S. Cordio, A. Passardi, E. Tamburini, L. Boni, A. Falcone, C. Cremolini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 years with ECOG PS ≤2 and between 71 and 75 years with ECOG PS = 0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender. Patients and methods: Subgroup analyses according to age (
Original languageEnglish
Pages (from-to)1969-1977
Number of pages9
JournalAnnals of Oncology
Volume30
Issue number12
DOIs
Publication statusPublished - Dec 1 2019

Keywords

  • age
  • FOLFOXIRI/bevacizumab
  • gender
  • metastatic colorectal cancer

Fingerprint Dive into the research topics of 'Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies'. Together they form a unique fingerprint.

Cite this